喻唯;刘小平;李胜;甘莉娟;龚青;

• 1:武汉大学健康学院
• 2:武汉大学中南医院泌尿外科
• 3:武汉大学中南医院生物样本库
• 4:武汉大学中南医院妇瘤科

摘要(Abstract)：

目的探索白细胞分化抗原6(cluster of differentiation 6, CD6)表达与子宫颈癌临床病理特征和预后的相关性,预测CD6影响肿瘤发生和发展的可能机制。方法下载TCGA-CESC数据集,使用R软件survminer包寻找截点,将资料按CD6表达量分为高表达组和低表达组。利用χ²检验比较两组各个临床病理特征的分布差异,生存分析采用Log-rank(Mantel-Cox)法。同时利用GSE44001数据集对生存分析结果进行验证。利用基因富集的方法探索CD6发挥作用的可能通路。结果子宫颈癌组织的CD6表达水平在肿瘤分期和组织学类型方面比较,差异均具有统计学意义(均P<0.05)。CD6低表达组5年总生存率和5年无瘤生存率均低于高表达组(均P<0.05)。基因富集的结果显示,CD6高表达组富集与调节免疫和细胞增殖分化相关的基因集。结论 CD6低表达与子宫颈癌不良预后相关,可能作为判断子宫颈癌预后的分子及治疗的靶标。

关键词(KeyWords)： 宫颈癌;CD6;预后;TCGA

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 喻唯;刘小平;李胜;甘莉娟;龚青;

DOI: 10.13267/j.cnki.syzlzz.2021.011

参考文献(References)：

• [1] Kontostathi G, Zoidakis J, Anagnou NP, et al. Proteomics approaches in cervical cancer:focus on the discovery of biomarkers for diagnosis and drug treatment monitoring[J]. Expert Rev Proteomics, 2016,13(8):731-745.
• [2] WHO. Human papillomavirus(HPV)and cervical cancer[EB/OL].(2019-1-24)[2019-10-12]. https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer
• [3] Wuerthner BA, Avila-Wallace M. Cervical cancer:Screening, management, and prevention[J]. Nurse Pract,2016,41(9):18-23.
• [4] Zhang L, Huang H, Zhang L, et al. URG4 overexpression is correlated with cervical cancer progression and poor prognosis in patients with early-stage cervical cancer[J].BMC Cancer, 2014,14(1):885.
• [5] Zong S, Liu X, Zhou N, et al. E2F7, EREG, miR-451a and miR-106b-5p are associated with the cervical cancer development[J]. Arch Gynecol Obstet, 2019,299(4):1089-1098.
• [6] Martínez VG, Moestrup SK, Holmskov U, et al. The conserved scavenger receptor cysteine-rich superfamily in therapy and diagnosis[J]. Pharmacol Rev, 2011,63(4):967-1000.
• [7] Li Y, Singer NG, Whitbred J, et al. CD6 as a potential target for treating multiple sclerosis[J]. Proc Natl Acad Sci U S A, 2017,114(10):2687-2692.
• [8] Consuegra-Fernández M, Lin F, Fox DA, et al. Clinical and experimental evidence for targeting CD6 in immune-based disorders[J]. Autoimmun Rev, 2018,17(5):493-503.
• [9] Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas(TCGA):an immeasurable source of knowledge[J]. Contemp Oncol(Pozn), 2015,19(1A):A68-77.
• [10] Bhat S, Kabekkodu SP, Noronha A, et al. Biological implications and therapeutic significance of DNA methylation regulated genes in cervical cancer[J]. Biochimie,2016,121:298-311.
• [11] Zhao F, Qiao Y. Cervical cancer prevention in China:a key to cancer control[J]. Lancet, 2019,393(10175):969-970.
• [12] Di J, Rutherford S, Chu C. Review of the cervical cancer burden and population-based cervical cancer screening in China[J]. Asian Pac J Cancer Prev, 2015,16(17):7401-7407.
• [13] Tsikouras P, Zervoudis S, Manav B, et al. Cervical cancer:screening, diagnosis and staging[J]. J BUON,2016,21(2):320-325.
• [14] Steenbergen RD, Snijders PJ, Heideman DA, et al. Clinical implications of(epi)genetic changes in HPV-induced cervical precancerous lesions[J]. Nat Rev Cancer,2014,14(6):395-405.
• [15] Dizon DS, Mackay HJ, Thomas GM, et al. State of the science in cervical cancer:where we are today and where we need to go[J]. Cancer, 2014,120(15):2282-2288.
• [16] Fox DA. The role of CD6 in autoimmune diseases[J]. Cell Mol Immunol, 2018,15(11):1001-1002.
• [17] Kofler DM, Farkas A, von Bergwelt-Baildon M, et al. The link between CD6 and autoimmunity:genetic and cellular associations[J]. Curr Drug Targets, 2016,17(6):651-665.
• [18] Consuegra-Fernández M, JuliàM, Martínez-Florensa M,et al. Genetic and experimental evidence for the involvement of the CD6 lymphocyte receptor in psoriasis[J]. Cell Mol Immunol, 2018,15(10):898-906.
• [19] Carrasco E, Escoda-Ferran C, Climent N, et al. Human CD6 down-modulation following T-cell activation compromises lymphocyte survival and proliferative responses[J]. Front Immunol, 2017,8:769.
• [20]徐帅师,聂文佳,张咏梅.子宫颈癌筛查中DNA倍体及HPV检查结果分析[J].实用肿瘤杂志, 2020,35(1):59-61.